FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma
FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational drug, plixorafenib. This designation applies to the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG)—a particularly aggressive and difficult-to-treat form of brain cancer.
This milestone marks a significant advancement not only for FORE Biotherapeutics but also for the broader field of neuro-oncology. According to the company, this is believed to be the first time a targeted therapy has received Breakthrough Therapy Designation specifically for high-grade glioma, highlighting the potential of plixorafenib to address a major unmet medical need.
Understanding Plixorafenib and Its Mechanism
Plixorafenib is a novel, investigational BRAF inhibitor designed with a unique mechanism known as a “paradox breaker.” Unlike traditional BRAF inhibitors, which can sometimes activate unintended signaling pathways, plixorafenib is engineered to selectively inhibit BRAF alterations without triggering paradoxical activation.
This selective activity is particularly important in cancers driven by BRAF mutations, especially the V600E mutation, which is a well-established oncogenic driver in several tumor types, including central nervous system (CNS) tumors.
The drug’s differentiated profile has shown promising activity in early clinical studies, particularly in tumors located in the brain and spinal cord—areas where treatment options remain limited and outcomes are often poor.
Significance of Breakthrough Therapy Designation
The FDA grants Breakthrough Therapy Designation to investigational treatments that demonstrate substantial improvement over existing therapies based on preliminary clinical evidence. This designation is intended for serious or life-threatening conditions and is designed to accelerate both development and regulatory review.
With BTD, FORE Biotherapeutics will benefit from:
- More frequent and intensive communication with the FDA
- Guidance from senior regulatory officials
- Eligibility for rolling review of a future New Drug Application (NDA)
- Potential priority review during the approval process
These advantages could significantly shorten the timeline required to bring plixorafenib to patients in need.
Clinical Evidence Supporting the Designation
The FDA’s decision was based on encouraging data from approximately 25 patients enrolled in a completed Phase 1/2a clinical trial, as well as ongoing results from the Phase 2 FORTE basket trial.
In these studies, plixorafenib demonstrated meaningful anti-tumor activity in patients with BRAF V600-mutated CNS tumors, including high-grade gliomas.
Key findings include:
- 67% overall response rate (ORR) in a pre-specified subgroup of patients
- Patients were MAPK inhibitor–naïve, indicating strong activity even without prior targeted therapy exposure
- Evidence of durable responses, supported by duration of response (DOR) and clinical benefit rate (CBR)
- Consistent activity across multiple CNS tumor histologies
These results suggest that plixorafenib may provide clinically meaningful benefits compared to currently available treatments.
The FORTE Basket Trial: Expanding the Evidence Base
The ongoing FORTE basket trial plays a central role in evaluating plixorafenib’s efficacy across a range of tumor types. This study includes patients with:
- High-grade gliomas (HGG)
- Low-grade gliomas (LGG)
- Other primary brain tumors
- Spinal cord tumors
Importantly, the trial includes both adult and pediatric patients, reflecting the broader potential application of plixorafenib in CNS malignancies.
The study recently passed a pre-specified interim analysis, with the Independent Data Monitoring Committee (IDMC) recommending continuation based on positive response assessments. The trial continues under close safety monitoring.
FORE Biotherapeutics expects to report topline results from the CNS cohort by the end of 2026, which could serve as the foundation for future regulatory submissions.
Pathway Toward Accelerated Approval
Based on current progress, FORE Biotherapeutics believes that, if the FORTE trial results remain positive, the data could support a New Drug Application (NDA) submission under the FDA’s Accelerated Approval pathway.
Accelerated approval allows drugs that treat serious conditions and address unmet needs to be approved based on surrogate endpoints, such as tumor response rates, rather than waiting for long-term survival data.
This pathway is particularly valuable in aggressive cancers like high-grade glioma, where patients urgently need new therapeutic options.
Additional Regulatory Designations
Plixorafenib has already received multiple FDA designations prior to this breakthrough:
- Fast Track Designation for cancers with BRAF Class 1 and Class 2 alterations
- Orphan Drug Designation (ODD) for primary brain and CNS malignancies
These designations collectively reinforce the importance of plixorafenib in addressing rare and serious cancers, while also providing regulatory incentives such as market exclusivity and development support.
Addressing an Urgent Unmet Need
High-grade gliomas are among the most aggressive and deadly forms of brain cancer. Despite advances in surgery, radiation, and chemotherapy, outcomes remain poor, with limited survival rates and significant treatment-related toxicity.
Patients often face:
- Rapid disease progression
- Neurological complications
- Limited effective treatment options
- High burden of treatment side effects
Medical experts emphasize the urgent need for therapies that are both more effective and better tolerated.
Plixorafenib’s targeted approach, combined with its favorable early safety and efficacy profile, positions it as a promising candidate to address these challenges.
Expert and Company Perspectives
Clinical experts have highlighted the importance of innovation in treating high-grade gliomas. Current therapies often fail to provide durable responses, and many patients experience significant side effects.
FORE Biotherapeutics’ leadership has also emphasized that the Breakthrough Therapy Designation validates the drug’s unique mechanism and clinical potential. The company believes that plixorafenib could play a key role in the molecularly guided treatment paradigm, where therapies are tailored based on specific genetic alterations like BRAF mutations.
The company remains committed to advancing the clinical program and working closely with regulators to bring this therapy to patients as quickly as possible.
Future Outlook
As the FORTE trial continues and additional data emerge, plixorafenib could become a cornerstone therapy for patients with BRAF-altered CNS tumors.
Key upcoming milestones include:
- Completion of the FORTE trial CNS cohort
- Release of topline data by late 2026
- Potential NDA submission under accelerated approval
- Continued expansion into additional BRAF-driven cancers
If successful, plixorafenib could represent a major breakthrough in the treatment of high-grade glioma and other CNS malignancies, offering new hope to patients facing limited options.About the Global Phase 2 FORTE Basket Study
The registration-intended FORTE Master Protocol is a global Phase 2 clinical trial which includes four sub-protocol baskets evaluating plixorafenib in distinct patient populations. The three monotherapy indications currently under evaluation are recurrent or progressive BRAF V600 primary CNS tumors, solid tumors with BRAF fusions and rare BRAF V600 mutated solid tumors. As part of the Bayesian adaptive design of the trial, interim efficacy analyses are conducted in each basket, for which the company reported a positive outcome from the BRAF V600 CNS basket in the third quarter of 2025.
About BRAF Altered Recurrent Primary CNS Tumors
BRAF altered recurrent primary CNS tumors represent a high unmet medical need and a large market opportunity for plixorafenib. In the advanced treatment setting, patients are offered currently approved therapies, but those therapies have significant limitations in efficacy, tolerability, and safety.
About Plixorafenib
Plixorafenib is a novel BRAF inhibitor, with a unique mechanism of action that functions both as a dimer and paradox breaker, and that has demonstrated a differentiated and compelling monotherapy profile in clinical studies. In a previously conducted Phase 1/2 study, in patients with MAPK inhibitor naïve BRAF V600 primary recurrent CNS tumors (n=9), plixorafenib monotherapy demonstrated an ORR of 67% and a clinical benefit rate of greater than 75%. In patients with V600 alterations who were MAPK inhibitor naïve, plixorafenib achieved a 42% response rate with prolonged duration of response (mDOR 17.8 months), with a clinical benefit rate of >70%. Plixorafenib also demonstrated a favorable safety and tolerability profile across tumor types, including relative to existing standard of care treatments for various BRAF altered tumors, with a discontinuation rate due to drug-related adverse events of less than 2%. Fore believes plixorafenib has the potential to overcome the limitations of currently available BRAF inhibitors through its unique mechanism of action targeting BRAF, while avoiding the limitations of the earlier generation BRAF inhibitors that led to rapid recurrence of disease and the need for combination with a MEK inhibitor.
About FORE Biotherapeutics
Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors.S
The FDA’s Breakthrough Therapy Designation for plixorafenib marks a pivotal moment in the development of targeted therapies for high-grade glioma. Supported by promising early clinical data and a robust development program, plixorafenib has the potential to significantly improve outcomes for patients with BRAF-mutated CNS tumors.
With multiple regulatory designations, ongoing clinical trials, and a clear path toward accelerated approval, FORE Biotherapeutics is advancing a therapy that could redefine the standard of care in one of oncology’s most challenging areas.
